premium than at present. The shares trade on 17x 18E PIE vs. 16x for peers. • Multiple catalysts from pipeline. Data on existing drugs Imfinzi and Lymparza in 1Q18, plus readouts on two potential blockbusters in roxadustat (anemia in chronic kidney disease) and anifrolumab (lupus) in the next 12 months